All In Biotech

Free tool

FAERS Monitor: Lucemyra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209229 or its brand name (Lucemyra, Lofexidine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

163

Serious

46

28% of reports

Hospitalization

24

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness24
  • hypotension17
  • somnolence15
  • dyspnoea14
  • diarrhoea13
  • dry mouth11
  • fatigue11
  • insomnia11
  • malaise10
  • vomiting10
  • withdrawal syndrome10
  • drug withdrawal syndrome9
  • loss of consciousness9
  • nausea9
  • fall8

Reports by year received

View as table
YearReports
20041
20051
20061
20111
20141
20155
20166
201819
201968
202023
20218
20229
20234
20248
20255
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
withdrawal syndromeSignal1030.716.9259
dry mouthSignal1117.59.9156
drug withdrawal syndromeSignal913.27.090
hypotensionSignal1710.97.0145
somnolenceSignal159.65.9108
loss of consciousnessSignal99.14.857
dizzinessSignal246.24.3102
insomniaSignal115.33.035
dyspnoeaSignal143.21.919
fallSignal83.11.610
malaiseSignal102.91.611
vomitingSignal102.71.510
diarrhoeaSignal132.61.512
fatigue111.81.03
nausea91.50.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.